GGrantIndex
Sort

23,748 grants matching melanoma

Project 3: Modeling and overcoming resistance to melanoma immunotherapy

$507,562
Antoni Ribas · University Of California Los Angeles · P01 · FY2023 · CA

BIOLOGY OF NONMELANOMA SKIN CANCER GROWTH &PROGRESSION

$507,388
University Of Texas Md Anderson Can Ctr · P01 · FY2002 · CA

DEVELOPMENT OF BIOMARKERS OF MINIMAL RESIDUAL DISEASE IN STAGE II MELANOMA USING DROPLET DIGITAL PCR-BASED ASSAYS TO DETECT CELL-FREE, METHYLATED DNAS IN PLASMA

$507,253
New York University · · FY2021 · Defense Health Agency

Identifying modifiable factors that reduce the burden of late stage melanoma in Hispanics

$507,130
Myles G Cockburn · University Of Southern California · R01 · FY2023 · CA

(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition

$507,066
Justin M Balko · Vanderbilt University Medical Center · R01 · FY2022 · CA

An Internet-Based Behavioral Intervention for Individuals Diagnosed with Melanoma

$507,030
Elliot J Coups · Rbhs -Cancer Institute Of New Jersey · R01 · FY2014 · CA

Community Outreach and Engagement

$506,901
Carmen E Guerra · University Of Pennsylvania · P30 · FY2024 · CA

Modulation of asparagine bioavailability and stress response signaling to enhance T cell robustness and maximize immunotherapy

$506,843
Ruoning Wang · Research Inst Nationwide Children'S Hosp · R01 · FY2021 · CA

PREDICTING EARLY-STAGE MELANOMA AT HIGH RISK OF RECURRENCE THROUGH MULTIOMICS PROFILING

$506,785
The University Of Queensland · · FY2025 · Defense Health Agency

Therapeutically harnessing anti-viral resident memory T cells in solid tumors

$506,676
Pamela Rosato · Dartmouth College · R01 · FY2023 · CA

Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma

$506,551
Christopher Austin Klebanoff · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA

Project 1: Nanotherapies for Vemurafenib Resistant Melanoma

$506,470
Leaf Huang · Univ Of North Carolina Chapel Hill · U54 · FY2016 · CA

Glycosylation Mutants of Mice and Animal Cells

$506,443
Pamela M Stanley · Albert Einstein College Of Medicine · R01 · FY2007 · CA

Administrative Core

$506,264
Raymond E Samuel · Hampton University · U54 · FY2013 · MD

CTLA-4 Inhibition and Autoimmunity in Melanoma

$506,157
University Of Southern California · R01 · FY2004 · CA

Efficacy of Web-based Training in Skin Cancer Triage

$506,111
Rhode Island Hospital · R01 · FY2005 · CA

The Genetics of Susceptibility to Mouse Plasma Cell Tumors

$506,056
Beverly Mock · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Repurposing drugs and finding new therapeutic targets for cutaneous malignancies

$505,981
Natasha Hill · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2023 · AR

Mcl-1 in apoptosis and signal transduction: a structure/function approach

$505,956
Maurizio Pellecchia · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2014 · CA

Functional Networks for Persister Cell Sensitivities

$505,756
Michael T McManus · University Of California, San Francisco · R01 · FY2020 · CA

Functional Networks for Persister Cell Sensitivities

$505,756
Michael T McManus · University Of California, San Francisco · R01 · FY2021 · CA

Localized immunotherapy using alum-binding therapeutics

$505,710
Darrell J Irvine · Massachusetts Institute Of Technology · R01 · FY2024 · EB

Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor Growth

$505,665
Theresa A Guise · Indiana University Indianapolis · U01 · FY2013 · CA

TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE

$505,476
Harvard University (Medical School) · R01 · FY2003 · EB

NCI National Clinical Trials Network – Network Lead Academic Participating Site

$505,438
Lawrence E Flaherty · Wayne State University · UG1 · FY2019 · CA